Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133887) titled 'Letrozole combined with famitinib for the treatment of platinum-resistant recurrent ovarian cancer with high estrogen receptor expression: A multicenter, open-label, randomized controlled phase II clinical trial' on Oct. 9.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Condition:
Estrogen receptor (ER) high-expression platinum-resistant recurrent ovarian cancer
Intervention:
Group A:Experimental Arm: Famitinib +letrozole
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2026-10...